ArticleCell chemical biology2017
Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.
Open access · bronzeAbstract read
In one paragraph
Article in Cell chemical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- A bypass gateway from cholesterol to sex steroid biosynthesis circumnavigates CYP17A1.Nature communications · 2025Article
- Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective.Pharmaceutics · 2024Review
- Targeting sex steroid biosynthesis for breast and prostate cancer therapy.Nature reviews. Cancer · 2023Review
- Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation.The Journal of clinical investigation · 2023Article
- Murine toxicology and pharmacokinetics of lead next generation galeterone analog, VNPP433-3β.Steroids · 2023Article
- Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.Oncogene · 2022Article
- The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients.Translational andrology and urology · 2022Article
- Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer.Cell reports. Medicine · 2022Article
- Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation.Science translational medicine · 2021Article
- Hormonal Therapy for Prostate Cancer.Endocrine reviews · 2021Review
- An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.International journal of molecular sciences · 2021Review
- Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on.Cancers · 2021Review
- Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism.Nature communications · 2021Article
- The role of adrenal derived androgens in castration resistant prostate cancer.The Journal of steroid biochemistry and molecular biology · 2020Review
- A new compound targets the AF-1 of androgen receptor and decreases its activity and protein levels in prostate cancer cells.American journal of cancer research · 2020Article
- Article
- HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.Endocrinology · 2019Review
- HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.The Journal of clinical investigation · 2018Article
- Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.Drug metabolism reviews · 2018Review
- Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.Chemical reviews · 2018Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 2 countries.
Mohammad AlyamaniDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Chemistry, Cleveland State University, Cleveland, OH 44115, USA.
Zhenfei LiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Michael BerkDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Jianneng LiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Jingjie TangCAS Key Laboratory of Systems Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, P.R. China.
Sunil UpadhyayDivision of Endocrinology and Metabolism, Department of Internal Medicine and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48103, USA.
Richard J AuchusDivision of Endocrinology and Metabolism, Department of Internal Medicine and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48103, USA.
Nima SharifiDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Chemistry, Cleveland State University, Cleveland, OH 44115, USA; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: sharifn@ccf.org.
Cleveland Clinic Lerner College of Medicine · USCleveland State University · USUniversity of Michigan · USChinese Academy of Sciences · CN
Funding
Elucidating a novel molecular biomarker for castration-resistant prostate cancerR01CA172382 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Nima Sharifi · 2012 to 2026
$5.2MCompensatory steroidogenesis mechanisms in castration-resistant prostate cancerR01CA190289 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SHARIFI, NIMA · 2015 to 2019
$2.1MCooperative steroidogenic inhibition for treatment of advanced prostate cancerR01CA168899 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SHARIFI, NIMA · 2013 to 2017
$1.6MNCI NIH HHS R01 CA168899NCI NIH HHS R01 CA172382NCI NIH HHS R01 CA190289
Abstract
Galeterone is a steroidal CYP17A1 inhibitor, androgen receptor (AR) antagonist, and AR degrader, under evaluation in a phase III clinical trial for castration-resistant prostate cancer (CRPC). The A/B steroid ring (Δ
Indexed as
17-Hydroxysteroid Dehydrogenases3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)3-Oxo-5-alpha-Steroid 4-DehydrogenaseAndrostadienesAnimalsBenzimidazolesCell Line, TumorChromatography, High Pressure LiquidHEK293 CellsHumansHydroxysteroid DehydrogenasesKaplan-Meier EstimateMaleMicePregnenoloneProstatic Neoplasms17-Hydroxysteroid Dehydrogenases3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene3 (or 17)-beta-hydroxysteroid dehydrogenase3-Oxo-5-alpha-Steroid 4-DehydrogenaseAKR1C2 protein, humanAndrostadienesBenzimidazolesCYP17A1 protein, humanHydroxysteroid DehydrogenasesPregnenoloneReceptors, AndrogenSteroid 17-alpha-Hydroxylase3βHSDabirateroneandrogensCYP17A1galeteronemetabolismprostate cancersteroids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.